Seeking Alpha

Bernstein comes out defending Celgene (CELG -11.5%) this morning after it takes a hit from...

Bernstein comes out defending Celgene (CELG -11.5%) this morning after it takes a hit from withdrawing Revlimid's front line and maintenance applications from Europe, saying the stock looks attractive at current levels. The firm expects the E.U. to eventually approve Revlimid and for the stock to recover over the near term. It reiterates its Outperform rating on the shares.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector